SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Resonance Health Limited’s FerriScan® R2-MRI Receives FDA Marketing Authorization as the First Imaging Companion Diagnostic Device for Exjade® in Patients With Non-Transfusion-Dependent Thalassemia (NTDT)